M. Gil

Interferon-gamma (INFG), an important marker of response to immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) and melanoma patients.

R. Rosell, N. Karachaliou, D. Rodríguez-Abreu, 2017 .

Targeting EML4-ALK driven non-small cell lung cancer (NSCLC).

R. Rosell, L. Vilà, E. Carcereny, 2013, Translational lung cancer research.

Liquid Biopsy in Non-Small Cell Lung Cancer

M. Catalán, R. Rosell, A. Giménez-Capitán, 2016, Front. Med..

Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)

R. Rosell, J. Ramírez, T. Bivona, 2017, Oncotarget.

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

I. Catalá, M. Esteller, A. Sieuwerts, 2016, Oncogene.

Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions

M. Catalán, R. Rosell, N. Viñolas, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion

R. Rosell, A. Giménez-Capitán, N. Karachaliou, 2018, OncoTargets and Therapy.

Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)

R. Rosell, J. Ramírez, T. Bivona, 2017, Oncotarget.